Revised Outlook: Theratechnologies and AngioDynamics Fall Short
- July 12th, 2023
- 401 views
Theratechnologies Inc. (Nasdaq: THTX) reported second-quarter fiscal 2023 revenue of $17.549 million, falling short of the consensus estimate of $20.32 million. The company attributes this lower-than-expected revenue to specialty pharmacy inventory adjustments that affected its consolidated revenue.
In light of the Q2 results, Theratechnologies has revised its full-year fiscal 2023 revenue guidance range to $82 million to $87 million, compared to the consensus estimate of $91.66 million.
In pre-market, $THTX is currently trading at $0.92, reflecting a decrease of $0.05 (5.07%).
In other news, AngioDynamics, Inc. (Nasdaq: ANGO) reported fourth-quarter fiscal 2023 earnings per share (EPS) of $0.02, in line with the consensus estimate.
Looking ahead, the company anticipates an adjusted loss per share for the full-year fiscal 2024, ranging from $0.28 to $0.34, contrasting with the consensus estimate of a loss of $0.02 per share.
$ANGO is currently trading at $9.75 in pre-market, down $0.19 (1.91%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Countdown to Earnings: Nutanix, CrowdStrike, and Synopsys on Deck
August 23rd, 2026Investors Eye Semtech, Intuit, and nCino as Earnings Loom
August 22nd, 2026FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
August 21st, 2026
Member Login